SLP

Simulations Plus Inc
NASDAQHEALTHCAREHEALTH INFORMATION SERVICES

Key Statistics

Market Cap
$370.72M
P/E Ratio
45.83
EPS
$0.40
Beta
1.31
52W High
$21.01
52W Low
$11.09
50-Day MA
$17.21
200-Day MA
$16.13
Dividend Yield
Profit Margin
9.88%
Forward P/E
52.91
PEG Ratio
9.88

About Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling, simulation, and prediction of molecule properties using artificial intelligence and machine learning technology worldwide. The company is headquartered in Lancaster, California.

Official WebsiteUSAFY End: August

Fundamentals

Revenue (TTM)$82.06M
Gross Profit (TTM)$52.01M
EBITDA$15.02M
Operating Margin22.80%
Return on Equity6.17%
Return on Assets5.48%
Revenue/Share (TTM)$4.07
Book Value$6.88
Price-to-Book2.67
Price-to-Sales (TTM)4.52
EV/Revenue3.914
EV/EBITDA18.77
Quarterly Earnings Growth (YoY)46.70%
Quarterly Revenue Growth (YoY)7.50%
Shares Outstanding$20.22M
Float$16.81M
% Insiders16.92%
% Institutions83.05%

Historical Volatility

HV 10-Day
2.57%
HV 20-Day
4.00%
HV 30-Day
31.69%
HV 60-Day
49.38%
HV Rank
1.6%

Volatility is currently contracting

Analyst Ratings

Consensus ($17.25 target)
5
Hold

Latest News

Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws

San Diego, California--(Newsfile Corp. - July 29, 2026) - Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholders The investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook. Investors who purchased Simulation Plus securities and suffered losses may have legal rights.

Newsfile Corp7/29/2026Neutral
SLP Shareholder Alert: Robbins LLP is Investigating Allegations that the Officers and Directors of Simulation Plus, Inc., Violated Securities Laws and Breached Fiduciary Duties to Shareholders

SAN DIEGO, July 28, 2026 /PRNewswire/ -- Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholders. The investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.

PRNewsWire7/29/2026Neutral
Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation

SAN DIEGO--(BUSINESS WIRE)---- $SLP #SimulationPlus--Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated securities laws or breached fiduciary duties owed to shareholdersThe investigation concerns whether Simulation Plus made materially false or misleading statements or omitted material information regarding its financial reporting, internal controls, and business outlook.Investors who purchased Simulation Plus securities and suf.

Business Wire7/28/2026Neutral
Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its third quarter fiscal 2026, ended May 31, 2026. Third Quarter 2026 Financial Highlights (as compared to third quarter 2025) Total revenue increased 7% to $21.9 million Software revenue was flat at $12.6 million, representing 58% o.

Business Wire7/9/2026Neutral
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures

SAN DIEGO, July 6, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. On April 3, 2025, Simulations Plus reported second-quarter fiscal 2025 financial results and maintained full-year revenue guidance of $90 million to $93 million.

PRNewsWire7/6/2026Neutral
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation concerns whether Simulations Plus or certain of its officers and directors made false or misleading statements, or failed to disclose material information, concerning the Company's financial outlook, reporting practices, internal controls, and related accounting matters.

PRNewsWire7/1/2026Neutral
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, July 01, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Simulations Plus, Inc. (“Simulations Plus” or “the Company”) (NASDAQ: SLP) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

GlobeNewsWire7/1/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SLP and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 7/29/2026